GoHealthcare Practice Solutions | Knowledge Center

GoHealthcare MSK Specialty Procedure Library™ | Ambulatory Surgery Center Operations

Implant Authorization

Device Authorization, Device-Intensive Payment, Pass-Through Status, and Implant Substantiation in the Ambulatory Surgery Center

An operational reference for implant-bearing ASC cases, including payer and vendor authorization, device-specific medical necessity, Medicare packaging and device-intensive payment, pass-through status, documentation, coding, and cost-risk controls.

Request HelpExplore the Guide

Publication and Use Information. This page is an educational and operational reference. It is not medical, legal, compliance, coding, or reimbursement advice and does not replace independent clinical judgment or verification of the payer, regulatory, coding, and payment requirements in effect for the specific patient and date of service. Authorization does not guarantee coverage or payment.

Up to 98%prior authorization approval rate reported in supported workflows

Operational performance depends on disciplined documentation and payer alignment.

GoHealthcare supports specialty practices and ASCs with prior authorization, utilization management, patient access, coding, revenue-cycle operations, compliance, and workflow optimization.

Review GoHealthcare case studies

Company-reported results vary by payer, patient population, clinical documentation, case mix, workflow design, and client execution.

Explore the Complete Guide

Use the links below to move directly to each section.

Guide Sections 1-8

1. Overview
2. Evidence at a Glance
3. Regulatory and Payment Foundation for Implants in the ASC
4. When Implant Authorization Is Triggered
5. Device Selection and Patient-Specific Justification
6. Coverage Exclusions and Investigational Device Status
7. Clinical Prerequisites for Implant-Bearing Procedures
8. Implant Documentation Requirements

Guide Sections 9-16

9. Imaging and Diagnostic Support for Device Selection
10. Medical Necessity for the Device Itself
11. Medicare Payment Architecture: Packaging, Device-Intensive, and Pass-Through
12. Commercial Payer and Vendor Implant Review
13. Implant Authorization Workflow
14. Common Implant Denials
15. Appeal Considerations for Device Denials
16. Coding and Billing Overview

Guide Sections 17-24

17. Device-Intensive Procedure Code Considerations
18. Device HCPCS Coding
19. Diagnosis Documentation for Implant Procedures
20. Modifiers, Credits, and Place of Service
21. Implant Documentation and Authorization Checklist
22. Setting Comparison: Implant Payment in the ASC and the Hospital Outpatient Department
23. GoHealthcare Clinical Insights
24. GoHealthcare Leadership Perspective

Guide Sections 25-32

25. GoHealthcare Case Study
26. GoHealthcare Best Practices
27. Common Mistakes
28. Pearls and Pitfalls
29. Frequently Asked Questions
30. Key Takeaways
31. Future Outlook
32. References

Guide Sections 33-38

33. Reading Recommendations
34. Related GoHealthcare Resources
35. Recommended Downloads
36. Visual Recommendations
37. Educational Disclaimer

01

Overview

Implants are where ambulatory surgery center economics become fragile. In a non-implant case, an authorization defect costs the facility a facility fee. In a device-intensive musculoskeletal case, the same defect costs the facility the facility fee plus the acquisition cost of an implant already opened, already in the patient, and already unrecoverable - and under several payer configurations it takes the anesthesia and professional claims with it. The asymmetry between the administrative effort required to prevent this and the loss incurred when it happens is larger than in any other area of ASC operations.

Implant authorization is also structurally different from procedure authorization, and the difference is not widely understood. For Medicare, the device usually has no independent authorization at all - it is packaged into the procedure payment, and the entire question is whether the facility has coded and documented in a way that captures the device portion of that payment. For several major commercial payers, by contrast, the device carries its own medical necessity determination: where a procedure code is delegated to a utilization management vendor, the associated device HCPCS codes are reviewed by that vendor as well. Two entirely different mechanisms, frequently operating on the same surgical schedule.

This guide covers both. It addresses the Medicare payment architecture for implants in the ASC - packaging, device-intensive methodology, device offset, pass-through status, and the credit and no-cost device rules - and the commercial and vendor review structures that attach medical necessity determinations to the device itself. It then addresses the documentation and coding that substantiate both, and the failure patterns that cost facilities the most money.

The timing is consequential. The CY 2026 addition of 560 surgical procedures to the ASC Covered Procedures List and the three-year elimination of the Inpatient Only list are moving implant-heavy musculoskeletal procedures into the ASC setting at a pace that outruns most facilities' implant supply chain, contracting, and authorization infrastructure. A newly eligible fusion code with no commercial carve-out, no implant cost model, and no device authorization pathway is not an opportunity. It is a scheduled loss.

Back to guide navigation

02

Evidence at a Glance

Domain	Current position (2026)
Medicare device authorization	There is generally no separate Medicare prior authorization for an implant. Device payment is packaged into the procedure payment except where pass-through status applies. The operative issues are coding, documentation, and correct application of the device-intensive methodology.
Device-intensive definition	Effective January 1, 2019, a procedure involving the surgical implantation or insertion of an implantable device assigned a CPT® or HCPCS code, including single-use devices, with a device offset amount exceeding 30 percent of the procedure's mean cost.
Default device offset	For new codes lacking claims data, CMS applies a default device offset percentage that is the greater of 31 percent or the applicable APC device offset percentage.
ASC payment indicators	Payment indicator J8 identifies a device-intensive procedure paid at an adjusted rate. Payment indicator J7 identifies an OPPS pass-through device paid separately when provided integral to a surgical procedure.
Device pass-through	Under section 1833(t)(6)(B) of the Social Security Act, device categories are eligible for transitional pass-through payment for at least two but not more than three years. CMS applies this policy in the ASC payment system as well.
Recent pass-through activity	HCPCS C1607 and C1608 were approved for pass-through status effective January 1, 2026. C1741 and C1742 took effect October 1, 2025; the C1741 long descriptor was revised to describe an absorbable metallic anchor or screw for bone fixation, which is directly relevant to musculoskeletal case mix.

Domain	Current position (2026)
Device reporting when no device is used	HCPCS C1890 is reported by the ASC alongside a device-intensive procedure code to signify that no implantable or insertable device was furnished. It is payable in the ASC setting only and is not reported on hospital outpatient institutional claims, where the equivalent bypass is modifier CG.
Unclassified devices	HCPCS C1889 describes an implantable or insertable device not otherwise classified, used where no specific device HCPCS code applies.
Code pair requirements	CMS publishes an ASC code pair file identifying the CPT® codes an ASC must perform in conjunction with a given device HCPCS code. Reporting a device code outside its permitted pairing will fail.
No-cost and credit devices	ASCs report modifiers FB and FC. Hospitals report value code FD with condition codes 49, 50, or 53; FB and FC were discontinued for hospital outpatient claims effective January 1, 2014. The divergence follows from the ASC billing on the professional claim format.
Commercial and vendor review	Several major payers delegate musculoskeletal and spine review to vendors including TurningPoint, Evolent, eviCore, Carelon, and Cohere. Under the common structure, where a CPT® code is delegated to the vendor, the associated device HCPCS codes are also reviewed by that vendor for medical necessity.
Claim-level vendor review	At least one major implant management program reviews both professional and facility claims and the plan reserves the right to adjust claims based on the vendor's recommendations. Authorization is therefore not the end of device review.
Investigational devices	Medicare may cover a Category B investigational device exemption device; a Category A device is not covered, although routine costs of care may be covered under the clinical trial policy. Commercial policies commonly exclude investigational devices outright.
Non-opioid pain devices	CMS finalized continuation of temporary additional payments for qualifying non-opioid treatments for pain relief in both the hospital outpatient department and ASC settings through December 31, 2027, identifying five drugs and eleven devices as separately payable in both settings starting in CY 2026.

Back to guide navigation

03

Regulatory and Payment Foundation for Implants in the ASC

Three separate frameworks govern an implant in an ASC, and they answer different questions. Confusing them produces most of the errors in this domain.

Framework	Question it answers	Authority
FDA regulatory status	May this device lawfully be marketed, and for what indication?	Federal Food, Drug, and Cosmetic Act; 510(k) clearance, premarket approval, De Novo classification, humanitarian device exemption, investigational device exemption.
Coverage	Will this payer pay for this device in this patient for this indication?	Medicare NCD, LCD, and Local Coverage Article; commercial medical policy; delegated vendor criteria.
Payment	How much, through what mechanism, and reported how?	ASC payment system; device packaging and device-intensive methodology; transitional pass-through; commercial contract terms and carve-outs.

A device can clear all three, or fail any one. FDA clearance does not create coverage. Coverage does not create separate payment. Separate payment does not survive incorrect coding. Facilities that treat these as a single question consistently discover the distinction at the point of denial.

How Medicare pays for implants in the ASC

The default rule is packaging. Under the revised ASC payment system, payment for implantable and insertable devices is packaged into the payment for the associated covered surgical procedure. The device is not separately payable, and the ASC must not report separate line items or separate charges for packaged items. Two structured exceptions modify this default.

Mechanism	How it works	Operational consequence
Device-intensive methodology (payment indicator J8)	Where the device offset exceeds 30 percent of the procedure's mean cost, the procedure is designated device-intensive and paid at an adjusted rate that reflects a larger device portion. The device remains packaged; the payment rate accounts for it.	The facility does not bill the device separately, but must report a device HCPCS code with the procedure. Failure to report a device code on a device-dependent procedure triggers an edit and a denial.
Transitional pass-through (payment indicator J7)	A device category granted pass-through status is paid separately when provided integral to a covered surgical procedure, for at least two but not more than three years under section 1833(t)(6)(B) of the Act. The device offset is deducted from the pass-through payment so the device is not paid twice.	Genuinely separate payment, but time-limited and category-specific. Pass-through status expires, and facilities that built a case economics model on pass-through payment must model the expiration.

The device offset

The device offset is the portion of the payment amount attributable to the device. It performs two functions. In the device-intensive methodology it determines whether a procedure qualifies and how the adjusted rate is constructed. In pass-through payment it is deducted so the device is not reimbursed twice. CMS publishes device offset percentages and device portions in the annual ASC addenda; Addendum FF contains applicable OPPS payment rates, APC device offset percentages, HCPCS device offset percentages, and device portions for covered surgical procedures.

Where a new HCPCS code describes a procedure requiring implantation or insertion of a single-use device meeting the device-intensive criteria and claims data are not yet available, CMS applies a default device offset percentage that is the greater of 31 percent or the applicable APC device offset percentage. This default matters operationally because it applies precisely to the newest, most expensive technology, where facility cost exposure is greatest and the payment rate is least informed by real claims experience.

The structural risk in the CY 2026 expansion

The default device offset is a rate-setting convention, not a cost reimbursement mechanism. It is derived from claims data that does not yet exist for the procedure in question. There is no guarantee - and frequently no realistic expectation - that it approximates a specific facility's acquisition cost for a specific implant system.

As newly eligible implant-bearing procedures migrate into the ASC under the CY 2026 Covered Procedures List expansion and the Inpatient Only list phase-out, facilities are encountering cases where the Medicare payment, including the device portion, does not cover the implant. This is not an authorization problem or a coding problem. It is a case selection and contracting problem, and it must be modeled before the first case is scheduled rather than discovered on the first remittance.

The discipline we recommend is simple and rarely practiced: before adding any device-intensive procedure to the schedule, model the expected Medicare payment against the actual negotiated implant cost, per implant system, per surgeon preference. Where the margin is negative, that is a decision for leadership, not a surprise for the business office.

Back to guide navigation

04

When Implant Authorization Is Triggered

Whether an implant requires its own authorization depends entirely on the payer and, where review is delegated, on the vendor's program structure. The determination must be made for the specific member and product, not inferred from the payer name.

Payer type	Typical device authorization posture	What to verify
Medicare fee-for-service	No separate device authorization. Device payment is packaged or paid under pass-through. The procedure may be subject to the OPD program, the ASC demonstration, or WISeR depending on setting and state, but the device itself is not separately authorized.	Which Medicare prior authorization regime, if any, applies to the procedure. See Guide B04-01.
Medicare Advantage	Plan-specific. Where the plan delegates surgical review to a vendor, the device commonly rides with the procedure delegation. Plans must apply Traditional Medicare coverage criteria where such criteria exist.	Whether the plan or a vendor reviews; whether device HCPCS codes are included in the delegation.
Commercial with delegated MSK or spine vendor	Under the common program structure, where a CPT® code is delegated to the vendor, the associated device HCPCS codes are also reviewed by that vendor for medical necessity. Some programs are explicitly designated as surgical and implantable device management programs.	The device code list included in the delegation; whether the vendor also reviews claims post-service.
Commercial without delegation	Device may be reviewed as part of the procedure authorization, may require separate pre-determination, or may be addressed only at the claim stage through invoice substantiation.	Whether the contract contains an implant carve-out and what substantiation it requires.
Workers' compensation	State fee schedules frequently address implant reimbursement separately and specifically, sometimes with invoice-plus-percentage formulas and caps.	The applicable state fee schedule provisions for implantables in the ASC setting, which vary substantially.
Medicaid and managed Medicaid	State-specific, frequently with additional device documentation requirements and shorter filing windows.	State plan and managed care organization requirements for the specific device category.

GoHealthcare Prior Authorization Insight: the device rides with the procedure

The single most important thing to understand about commercial implant authorization is the delegation-rider structure. Payer authorization grids increasingly state it explicitly: if a procedure code is delegated to the utilization management vendor, the associated device HCPCS codes are also reviewed by that vendor for medical necessity.

Two consequences follow, and facilities routinely miss both.

• First, the device is being reviewed whether or not anyone submitted it. If the authorization request described the procedure but not the device, the vendor reviewed the device on whatever information it had - which may be none.
• Second, an approved procedure does not mean an approved device. A partial determination approving the procedure while denying or limiting the device is a real outcome, and it is the one that strands an implant cost.

The operational fix is to specify the anticipated device category and, where the policy addresses it, the specific system, in the original authorization request. It costs nothing at submission and is unrecoverable afterward.

Back to guide navigation

05

Device Selection and Patient-Specific Justification

Payer and vendor criteria increasingly address device selection, not merely procedure appropriateness. Several musculoskeletal criteria sets contain explicit device consideration sections addressing indication, patient characteristics, and in some cases specific manufacturer information. Where such a section exists, the authorization submission should be constructed to answer it directly.

What device-level criteria typically address

Dimension	Typical requirement	Documentation
FDA-cleared or approved indication	The device must be used within its cleared or approved indication, or the request must address off-label use explicitly.	Identify the device and state the indication being treated. Off-label use requires affirmative clinical justification and is a common denial basis.
Patient anatomy and sizing	Device dimensions appropriate to the patient's anatomy as demonstrated on imaging.	Imaging measurements where the policy requires them; templating documentation for arthroplasty and interbody applications.
Trial or staged requirement	For neuromodulation, a successful trial is generally a prerequisite to permanent implantation, with defined response thresholds and documentation.	Trial dates, duration, response measured against the policy's threshold, and functional outcome. Trial documentation is the single most scrutinized element in neurostimulation authorization.
Rechargeable versus non-rechargeable	Some policies address generator selection, including patient ability and willingness to manage a rechargeable system.	Document the selection rationale, including patient factors bearing on recharging capability and expected longevity considerations.
MRI conditionality	Where the patient has a foreseeable future imaging need, MRI conditional labeling may be a selection factor.	Document the anticipated imaging need and the conditionality of the selected system.
Waveform, closed-loop, and programming features	Advanced features may be addressed in policy, and some are the subject of specific coverage positions.	Where a feature-specific system is selected, document the clinical rationale rather than relying on surgeon preference alone.
Revision and explant history	Prior device at the same site, reason for failure, and interval.	Prior operative reports, device identifiers of the explanted system, and documented failure mode.
Biologics and graft materials	Bone graft substitutes, allograft, and biologics frequently carry their own coverage positions, several of which are restrictive.	Verify the specific material's coverage posture separately from the procedure. This is a frequent and expensive oversight in fusion cases.

Device landscape by musculoskeletal procedure family

The table below identifies the manufacturers and systems most frequently encountered by procedure family in musculoskeletal specialty practice, as an orientation to what an authorization team will see. It is not a coverage statement, a comparative assessment, or an endorsement. FDA status, cleared indications, MRI conditionality, current labeling, and payer coverage position must be verified against current manufacturer labeling and current payer policy for every case, and are subject to the clinical and device review gate recorded in Section 37 of this guide.

Procedure family	Manufacturers commonly encountered	Attributes to verify per case
Spinal cord stimulation	Medtronic; Abbott; Boston Scientific; Nevro; Saluda.	Cleared indications including any condition-specific indication; trial requirement and documentation; rechargeable versus non-rechargeable; waveform and closed-loop features; MRI conditionality; generator and lead HCPCS assignment; payer position on the specific waveform or feature.
Dorsal root ganglion stimulation	Abbott.	Approved indication and anatomic scope; trial requirement; payer position, which is more restrictive than for conventional spinal cord stimulation at several payers.
Peripheral nerve stimulation	SPR Therapeutics; Nalu; Curonix; Bioness.	Cleared indication and duration of therapy, including whether the system is temporary or permanent; nerve target; payer coverage position, which varies widely and is frequently the limiting factor.

Procedure family	Manufacturers commonly encountered	Attributes to verify per case
Intrathecal drug delivery	Medtronic; Flowonix.	Approved agents and concentrations; refill and programming considerations; MRI protocol; trial requirement; pump and catheter coding.
Interbody fusion and spinal instrumentation	Medtronic; Stryker; Globus Medical; Zimmer Biomet; Orthofix; Alphatec; SeaSpine.	Cage material and design; expandable versus static; pedicle screw system; navigation or robotic assistance and its separate coverage posture; bone graft or biologic material coverage, verified separately.
Cervical and lumbar disc arthroplasty	Multiple manufacturers with device-specific approvals.	Approved level and indication scope, which is device-specific and narrower than many assume; payer coverage position, which varies by level and by single versus multi-level.
Sacroiliac joint fusion	Multiple manufacturers with differing approaches.	Approach and device type, which several payer policies treat differently; diagnostic block requirements; conservative care duration.
Vertebral augmentation	Multiple manufacturers.	Device type; fracture age and imaging requirements; coverage posture, noting inclusion in the WISeR Model service list.
Large joint arthroplasty	Stryker; Zimmer Biomet; DePuy Synthes; Smith & Nephew.	Implant system and any robotic or navigation assistance; ASC Covered Procedures List status for the specific code; implant cost against expected payment, which is the binding constraint in the ASC setting.
Soft tissue repair and fixation	Multiple manufacturers of anchors, screws, and fixation devices.	Whether an applicable device HCPCS code exists or C1889 applies; any pass-through category in effect, noting the absorbable metallic bone fixation anchor or screw category effective October 1, 2025.

Back to guide navigation

06

Coverage Exclusions and Investigational Device Status

Exclusion	Effect	Control
Investigational or experimental under payer policy	Denied on that basis regardless of documentation quality. Many commercial policies exclude investigational devices categorically.	Determine coverage posture before scheduling. A clinical argument does not overcome a categorical policy exclusion.
Category A investigational device exemption	The device itself is not covered by Medicare. Routine costs of care may be covered under the clinical trial policy.	Confirm IDE category and study approval status before the case; the financial structure differs fundamentally from Category B.
Category B investigational device exemption	The device may be covered by Medicare where applicable requirements are met.	Confirm study approval, device category determination, and contractor requirements in advance.
Off-label use	Not automatically excluded, but frequently denied absent affirmative justification.	Address off-label use explicitly in the authorization request rather than omitting it.
Humanitarian device exemption	Coverage posture varies; several payers treat HDE devices restrictively.	Verify payer position specifically; do not assume parity with cleared or approved devices.
Device not on the facility's contract or carve-out schedule	Implant cost may be unrecoverable even where the procedure is authorized and paid.	Contract review before adding an implant system to the preference card.

Exclusion	Effect	Control
Procedure not on the ASC Covered Procedures List	No Medicare facility payment at all, device included.	Scheduling edit against the current list and annual addenda.
Packaged item billed separately	Inappropriate billing of an item packaged into the procedure allowance.	Charge master governance and periodic packaging audit.

Back to guide navigation

07

Clinical Prerequisites for Implant-Bearing Procedures

Implant-bearing musculoskeletal procedures generally carry the most demanding conservative care and diagnostic prerequisites of any category in payer policy, because they are the highest cost and the least reversible. The general principles are set out in Guide B04-01, Section 7. What follows are the prerequisites specific to implant categories.

Category	Typical prerequisite structure
Neuromodulation	Documented diagnosis within the covered indication; failure of conservative care including pharmacologic and non-pharmacologic therapy over a specified duration; psychological evaluation where the policy requires it; a successful trial meeting a defined response threshold, with the trial itself frequently requiring separate authorization; and absence of untreated conditions the policy identifies as exclusions.
Spinal fusion and instrumentation	Imaging demonstrating the specific pathology at the specific level; correlation of the imaging finding to the clinical presentation; documented conservative care duration; functional impairment measured with a validated instrument where required; and for instability indications, dynamic imaging where the policy specifies it.
Disc arthroplasty	Level-specific and indication-specific criteria that are frequently narrower than for fusion at the same level, with explicit exclusion criteria addressing facet arthropathy, instability, and prior surgery.
Sacroiliac joint fusion	Diagnostic block response meeting a defined threshold, frequently requiring more than one block; conservative care duration; and exclusion of alternative pain generators.
Large joint arthroplasty	Radiographic severity criteria; documented functional limitation; conservative care including physical therapy and where required intra-articular injection; and in the ASC setting, site-of-service appropriateness addressed separately.
Vertebral augmentation	Fracture confirmation and age on appropriate imaging; failure of conservative management over a defined interval; correlation of the fracture level to the pain generator.

Where a trial is required - most prominently in neuromodulation - the trial documentation is the substance of the permanent implant authorization. Response should be documented against the policy's stated threshold, in the policy's own terms, with dates, duration, pain scores, functional change, and medication change. A trial documented as 'successful' without measurement is the most common cause of denial for permanent implantation.

Back to guide navigation

08

Implant Documentation Requirements

Implant documentation serves the medical record requirement at 42 CFR 416.47, the device HCPCS coding that captures device-intensive or pass-through payment, the payer's substantiation requirement, and recall traceability. It must be captured at the point of use; reconstruction from purchasing records after the fact is neither reliable nor defensible.

• Device name, manufacturer, and model, recorded in the medical record and not solely in a separate implant log
• Lot number, serial number, or unique device identifier where applicable
• Size, dimensions, and where relevant material
• Anatomic site, level, and laterality of placement
• Quantity, including multiples and each component of a multi-component system

• Explanted device with identifiers and disposition, including return to manufacturer
• Device HCPCS code assigned, reconciled against the ASC code pair file for the procedure performed
• Where no device was used in a device-intensive procedure, documentation of that fact supporting reporting of C1890
• Where a device was furnished without cost or with credit, documentation supporting the credit and its amount
• Manufacturer invoice where the payer contract requires invoice substantiation
• For trial-then-permanent implant sequences, linkage between the trial documentation and the permanent implant record
• Sterilization and, where applicable, loaner or consignment tray documentation

The implant log is not the medical record

A recurring finding in ASC record review is complete implant detail residing in a standalone implant log, an inventory system, or a purchasing record, with the medical record containing only a generic reference to hardware placement.

This fails on three fronts simultaneously. It is a medical record content deficiency under 42 CFR 416.47(b)(4), which requires findings and techniques of the operation. It leaves the device HCPCS code unsupported in an audit. And it makes recall response dependent on a system that may not be retained as long as the medical record is.

The log remains valuable operationally. It is not a substitute. The implant detail must appear in the operative report or in a documented part of the medical record.

Back to guide navigation

09

Imaging and Diagnostic Support for Device Selection

Purpose	Requirement	Failure mode
Establishing the indication	Imaging of the modality the policy specifies, within its recency window, correlated by the treating physician to the clinical presentation at the specific level and side.	Radiology report attached without physician correlation. See Guide B04-01, Section 9.
Supporting device selection and sizing	Measurements, templating, or anatomic assessment where the policy or the device requires it.	Sizing determined intra-operatively with no pre-operative documentation, leaving a device-level determination unsupported.
Demonstrating instability or alignment	Dynamic, weight-bearing, or standing imaging where the indication depends on it.	Static imaging submitted for an instability indication that requires dynamic study.
Establishing prior construct status	Imaging demonstrating the existing hardware, its position, and any failure.	Revision requested without imaging documenting the failure mode of the prior construct.
Post-operative confirmation	Imaging confirming device position where clinically indicated.	Not a coverage requirement in most policies but material to the clinical record and to complication documentation.

Back to guide navigation

10

Medical Necessity for the Device Itself

Where a payer reviews the device separately, the submission must establish two propositions rather than one: that the procedure is necessary, and that this device is the appropriate device for this patient. The second is frequently unaddressed, because clinicians reasonably regard device selection as within their professional judgment. Payers with device-level criteria do not treat it that way.

Constructing the device justification

• Name the device or, where the policy operates at the category level, the device category.

• State the FDA-cleared or approved indication being treated, and where use is outside labeling, state that affirmatively with clinical justification.
• Address any device-specific criterion the policy contains, in the policy's own terms and order.
• Where a trial was required, state the trial dates, duration, and measured response against the policy's threshold.

• Where the policy addresses generator type, MRI conditionality, or specific features, address the selection rationale in patient-specific terms.
• Where an alternative device or approach would ordinarily be expected, explain why it is not appropriate for this patient.
• Where the device is a revision or replacement, document the prior device, the failure mode, and the interval.

GoHealthcare Clinical Insight: surgeon preference is not a medical necessity argument

Device selection in musculoskeletal practice is genuinely driven in part by surgeon familiarity, and that is clinically legitimate - a surgeon operating with a system they know well is a safety consideration. But it is not an argument a utilization reviewer can act on, and submissions that rest on it implicitly tend to fail.

The reframing that works is to state the patient-specific attribute the selected system provides: the anatomic fit, the anticipated imaging need addressed by conditional labeling, the revision compatibility with existing hardware, the trial response to a specific waveform. These are properties of the patient's situation rather than of the surgeon's practice, and they are reviewable.

Where the honest answer is that any of several comparable systems would serve, the stronger submission addresses the device at the category level and does not invite a device-specific challenge that does not need to be had.

Back to guide navigation

11

Medicare Payment Architecture: Packaging, Device-Intensive, and Pass-Through

Reading the payment indicator

The ASC payment indicator assigned to a procedure or device code determines the payment mechanism and drives the implant workflow. Payment indicators are published in the annual ASC addenda and are updated quarterly. Two are central to implant operations.

Indicator	Meaning	Implant workflow consequence
J8	Device-intensive procedure; paid at an adjusted rate.	A device HCPCS code must be reported with the procedure. Where genuinely no device was used, C1890 must be reported instead. Omitting both triggers the device edit and denies the claim.
J7	OPPS pass-through device paid separately when provided integral to a covered surgical procedure.	Report the device code for separate payment. Verify the pass-through category remains active for the date of service and confirm the permitted procedure pairing.

The device edit and the code pair file

The Medicare outpatient code editor identifies claims reporting a procedure assigned to a device-dependent classification without at least one required device HCPCS code. This is a mechanical edit and it denies mechanically. CMS separately publishes an ASC code pair file identifying the CPT® codes an ASC must perform in conjunction with a given device HCPCS code. Reporting a device code outside its permitted pairing fails just as reporting no device code does.

Scenario	Correct reporting
Device-intensive procedure with a device having a specific HCPCS code	Report the procedure code with the applicable device HCPCS code, verified against the current ASC code pair file.

Scenario	Correct reporting
Device-intensive procedure with a device having no specific HCPCS code	Report C1889, implantable or insertable device not otherwise classified.
Device-intensive procedure where no implantable or insertable device was furnished	Report C1890 alongside the procedure code. C1890 is payable in the ASC setting only and is not reported on hospital outpatient institutional claims, where the equivalent bypass is modifier CG.
Revision or removal without placement of a new device	This is the classic C1890 scenario. Where a generator or component is revised or removed without a new device being furnished, reporting a device HCPCS code for a device that was not supplied is incorrect; C1890 signals the absence.
Device with active pass-through status	Report the pass-through device code for separate payment, confirming the category is active for the date of service and that the procedure pairing is permitted.
Packaged supply or item	Do not report separately. ASCs must not report separate line items or charges for items packaged into the covered surgical procedure allowance.

No-cost and credit devices

Where a device is furnished without cost or with credit, Medicare reduces payment so the program does not reimburse a cost the facility did not incur. The mechanism differs by setting, and the divergence is a persistent source of error in organizations operating both an ASC and a hospital outpatient department.

Setting	Reporting mechanism	Payment effect
Ambulatory surgery center	Modifier FB where the device was furnished without cost to the provider or full credit was received for a replaced device. Modifier FC where partial credit of 50 percent or more of the device cost was received.	For no-cost or full-credit replacement, payment is reduced by the device portion of the ASC payment. For partial credit, the reduction is one-half of the device offset amount.
Hospital outpatient department	Value code FD with the credit amount, reported with condition code 49, 50, or 53 as applicable. Modifiers FB and FC were discontinued for hospital outpatient claims effective January 1, 2014.	Payment reduced consistent with 42 CFR 419.45, subject to the applicable limitation on the deduction amount.

The reason for the divergence is structural rather than arbitrary: the ASC bills on the professional claim format, which has no value code or condition code fields. Facilities should not attempt to harmonize the two, and organizations operating both settings should maintain separate work instructions.

Device credit reporting is an established audit target

Device credit and no-cost device reporting has been the subject of repeated Office of Inspector General audit activity, with findings of underreported credits producing overpayments. The exposure is asymmetric: failing to report a credit is an overpayment, and overpayments carry identification and return obligations.

The practical control is a defined process linking the materials management function to the billing function. Warranty replacements, recall replacements, field actions, clinical trial devices, and free samples must reach the coder before the claim is submitted. In most facilities where we find this control absent, no one has affirmatively decided not to report credits - the two functions simply never connected.

Back to guide navigation

12

Commercial Payer and Vendor Implant Review

Payer or vendor	Implant review posture	Operational emphasis
TurningPoint Healthcare Solutions	Administers surgical and implantable device management programs for several plans across orthopedic, spine, and cardiac service lines. Where a CPT® code is delegated, associated device HCPCS codes are also reviewed for medical necessity. At least one program reviews both professional and facility claims, with the plan reserving the right to adjust claims based on the vendor's recommendations.	Device specification belongs in the original request. Post-service claim review means authorization is not the end of exposure. Criteria sets include explicit device consideration and documentation sections.
Evolent	Administers musculoskeletal management programs for several plans. Under the same structure, device HCPCS codes associated with a delegated CPT® code are reviewed for medical necessity.	Confirm program scope for the specific plan and product; delegation has moved between vendors at several plans in recent years.
eviCore healthcare	Delegated musculoskeletal, spine, and interventional pain review. Device considerations appear within procedure criteria, particularly for neuromodulation.	Trial documentation for neurostimulation is the highest-yield element. Submit through the portal with complete clinical attachment.
Carelon Medical Benefits Management	Delegated musculoskeletal, spine, joint, and pain programs. Guideline versions are dated and updated on a defined cycle.	The guideline version in effect on the date of service governs. Verify the current version each batch rather than assuming carryover.
Cohere Health	Episode-based authorization across musculoskeletal service lines.	Understand what the authorized episode includes with respect to devices, to avoid both redundant requests and unauthorized adjuncts.
UnitedHealthcare	Prior authorization with site-of-service review; published facility reimbursement policy addresses devices, implants, and skin substitutes, including the requirement that a device or implant be submitted on the same claim and date of service as the procedure, with device-dependent procedures denied where reported without an applicable device.	The same-claim, same-date requirement is mechanical and is a frequent avoidable denial.
Aetna, Cigna, Humana	Coverage policies address specific device categories, with several neuromodulation and spine device positions materially more restrictive than Medicare.	Read the device-specific policy, not only the procedure policy. Positions diverge most for newer device categories.
Blue Cross Blue Shield plans	Independent licensees with materially different device policies, vendors, and carve-out structures by state and product.	Never generalize. BlueCard out-of-area members follow the home plan's medical policy while the local plan handles claims.
Workers' compensation	State fee schedules frequently address implant reimbursement explicitly, in some states through invoice-plus-percentage formulas with per-item and per-admission caps.	Implant reimbursement may be materially better or worse than commercial. Model it by state before accepting the case.

Contract structures for implant reimbursement

Structure	How it works	Risk
Fully packaged	The contracted procedure rate includes the implant with no separate reimbursement.	All implant cost risk sits with the facility. Viable only where the rate was modeled against actual implant cost for the specific systems in use.
Implant carve-out at invoice	Implant reimbursed at documented invoice cost, sometimes with a threshold below which no carve-out applies.	Requires invoice substantiation discipline. Thresholds are frequently misunderstood, and implants below the threshold are an unmodeled loss.

Structure	How it works	Risk
Invoice plus percentage	Invoice cost plus a stated percentage, sometimes with a cap.	The percentage must be modeled against actual carrying, handling, and financing cost. Caps convert high-cost cases into losses.
Percentage of billed charges	Implant reimbursed as a percentage of charges.	Depends entirely on charge master integrity. A charge master not maintained against implant cost erodes silently.
Case rate	A single rate for the episode including implant.	Same risk profile as fully packaged, with additional exposure where the case rate assumes a device mix the facility does not actually use.

Back to guide navigation

13

Implant Authorization Workflow

Stage	Actions	Failure if skipped
1. Preference card and device determination	Identify the anticipated implant system and components from the surgeon's preference card and the planned procedure, before authorization is requested.	Authorization submitted with no device information, leaving a device-level determination to be made on no information.
2. Coverage and contract screening	Verify the device's coverage posture with the payer and, separately, whether the facility's contract reimburses the implant and on what basis.	An authorized procedure with an unreimbursed implant. Coverage and contract are different questions.
3. Cost and margin modeling	Model expected payment, including the device portion, against actual negotiated implant cost for the specific system.	Negative-margin cases scheduled without a leadership decision.
4. Vendor determination	Determine whether device review is delegated, and whether device HCPCS codes are included in the delegation for this member and product.	Device reviewed by a vendor that never received device information.
5. Authorization request	Submit with the procedure and the anticipated device category or system specified, addressing any device-level criteria in the policy's own terms.	Partial determination approving the procedure and denying or limiting the device.
6. Determination capture	Capture what was authorized at the device level: category, system, quantity, and any limitation, into the facility record.	The facility cannot tell before the case whether the device is covered.
7. Supply chain confirmation	Confirm the authorized system is available, on contract, and that consignment or loaner logistics are arranged.	Substitution at the point of use to a system that was not authorized and may not be reimbursed.
8. Pre-service reconciliation	Reconcile the authorized device against the planned device alongside the seven-field procedure reconciliation described in Guide B04-01.	Device mismatch discovered after the implant is in the patient.
9. Point-of-use capture	Capture device detail into the medical record at the time of use, including any intra-operative substitution.	Reconstruction from purchasing records, which is unreliable and indefensible.
10. Intra-operative substitution management	Where the device used differs from the device authorized, flag the case the same day.	A denial thirty days later with no contemporaneous documentation of why the substitution occurred.
11. Coding and device edit reconciliation	Assign the device HCPCS code, verify it against the ASC code pair file, and confirm the device edit is satisfied. Where no device was used in a device-intensive procedure, report C1890.	Mechanical device edit denial, which is entirely preventable.

Stage	Actions	Failure if skipped
12. Credit and no-cost reporting	Route warranty replacements, recall replacements, clinical trial devices, and free samples from materials management to coding before claim submission.	Unreported credit, which is an overpayment carrying identification and return obligations.
13. Invoice substantiation	Where the contract requires it, attach or retain the manufacturer invoice per the payer's requirement.	Carve-out payment denied for want of substantiation the facility possessed.
14. Outcome capture	Record device-level determination outcomes and denial reasons in structured fields.	Recurring device denials invisible in aggregate reporting.

Back to guide navigation

14

Common Implant Denials

Denial	Category	Root cause	Prevention
Device-dependent procedure reported without a device HCPCS code	Mechanical	Device code omitted, or C1890 not reported where no device was used.	Device edit reconciliation before submission; C1890 discipline for revision and removal cases.
Device code not permitted with the procedure reported	Mechanical	Code pair requirement not verified.	Verification against the current ASC code pair file.
Device and procedure not on the same claim and date of service	Mechanical	Split billing or a late-added device line.	Claim assembly control; several commercial policies deny device-dependent procedures reported without the device on the same claim.
Device not authorized although the procedure was	Clinical or administrative	Device not specified in the request where the vendor reviews device codes under the delegation.	Specify the device category or system in the original request.
Device considered investigational or experimental	Policy	Coverage posture not determined before scheduling.	Pre-scheduling coverage determination; a clinical argument does not overcome a categorical exclusion.
Off-label use not justified	Clinical	Use outside cleared or approved labeling not addressed affirmatively.	Address off-label use explicitly with clinical justification.
Trial documentation insufficient for permanent implantation	Clinical	Trial documented as successful without measurement against the policy threshold.	Trial dates, duration, measured response, functional change, and medication change documented against the policy's stated threshold.
Device substituted intra-operatively without documentation	Administrative	No substitution management pathway.	Same-day flagging with contemporaneous documentation of the clinical reason.
Invoice substantiation not provided	Administrative	Carve-out requirement not recorded in the payer matrix.	Invoice requirement recorded as a distinct field; invoice retained at the point of purchase.
Biologic or graft material not covered	Policy	Coverage of the graft material assumed to follow the fusion procedure.	Verify biologic and graft coverage separately from the procedure. A frequent and expensive oversight.

Denial	Category	Root cause	Prevention
Pass-through status expired	Administrative	Case economics modeled on pass-through payment that lapsed.	Track pass-through category expiration dates; status runs at least two but not more than three years.
Device credit not reported	Compliance	Materials management and billing not connected.	Defined routing process for warranty, recall, trial, and sample devices.
Implant billed separately when packaged	Compliance	Charge master or billing practice not aligned to packaging rules.	Charge master governance and periodic packaging audit.

Back to guide navigation

15

Appeal Considerations for Device Denials

Device denials divide cleanly into categories with very different prospects, and correctly classifying the denial before responding saves substantial effort.

Denial type	Prospect	Approach
Mechanical or edit denial	High. These are correctable.	Correct and resubmit. Do not file a clinical appeal against a mechanical edit; it is a common and costly misclassification.
Device not authorized where the procedure was	Moderate.	Establish that the device was integral to the authorized procedure and address the device-level criteria that were never submitted. Retrospective authorization or a documented exception pathway may be available.
Insufficient trial documentation	Moderate to high if the trial data exists.	Produce the measured trial response against the policy threshold. Where the measurement was never taken, the appeal is weak and the lesson is prospective.
Off-label use	Moderate.	Affirmative clinical justification, supporting peer-reviewed literature, and an explanation of why labeled alternatives are not appropriate for this patient.
Investigational or experimental determination	Low.	This is a policy position rather than a documentation gap. Appeals rarely succeed. Determine posture before scheduling.
Contract or carve-out dispute	Variable.	Not a medical necessity appeal at all. This is a contract dispute and belongs with contracting and, where warranted, counsel.
Payment amount below implant cost	Not appealable.	This is a rate and contracting issue, not a claims issue. It is resolved at negotiation or through case selection.

Back to guide navigation

16

Coding and Billing Overview

• Determine whether the procedure carries payment indicator J8. If it does, a device HCPCS code or C1890 must accompany it.
• Assign the most specific device HCPCS code available; use C1889 where no specific code applies.
• Verify the device code against the current ASC code pair file for the procedure performed.
• Report devices with active pass-through status separately, confirming the category is active for the date of service.
• Do not report separately any item packaged into the covered surgical procedure allowance.
• Report the device and the procedure on the same claim and the same date of service; several commercial policies deny device-dependent procedures reported otherwise.

• Apply FB or FC where a device was furnished without cost or with credit, supported by documentation of the credit and its amount.

• Code from the operative report. Where the device documented differs from the device authorized, code what was used and manage the variance.

• Detailed reimbursement methodology, fee schedules, and payment rates are addressed in Guides B04-07 and B04-09 and in the GoHealthcare Revenue Cycle Knowledge Center.

Back to guide navigation

17

Device-Intensive Procedure Code Considerations

Consideration	Operational requirement
Device-intensive designation	Designation is assigned annually and can change. CMS publishes the device-intensive procedure list in the annual rule addenda; a procedure designated device-intensive in one year may not be in the next, and the reverse.
Payment indicator verification	Verify the current payment indicator for each device-intensive procedure the facility performs, at the annual update and at quarterly updates.
ASC Covered Procedures List status	Device-intensive designation is irrelevant if the procedure is not on the ASC Covered Procedures List for the applicable year.
Multiple procedure reduction	The ASC multiple procedure reduction applies to procedures performed in the same operative session, with the highest-valued procedure paid at full rate and additional procedures at a reduced rate. Device-intensive procedures interact with this reduction, and the interaction should be modeled for multi-procedure implant cases.
Discontinued procedures	Where a device-intensive procedure is discontinued, the point of termination determines modifier selection and affects payment. Where an implant was opened but not implanted, the cost is incurred without a corresponding implant to report.
New codes without claims data	Expect the default device offset that is the greater of 31 percent or the applicable APC device offset percentage, and model accordingly rather than assuming the rate reflects actual device cost.
Annual and quarterly updates	Device-intensive designations, payment indicators, code pair files, and pass-through categories all change on published cycles. A January-only review is insufficient; quarterly updates matter for device operations specifically.

Back to guide navigation

18

Device HCPCS Coding

Code or category	Application
C-codes generally	Temporary HCPCS codes describing devices, used by facilities under the outpatient prospective payment system and applied in the ASC setting for device reporting and pass-through payment.
C1889	Implantable or insertable device, not otherwise classified. Used where no specific device HCPCS code describes the device furnished.
C1890	No implantable or insertable device used with device-intensive procedures. Reported by the ASC alongside the device-intensive procedure code to signify that no device was furnished. Payable in the ASC setting only; not reported on hospital outpatient institutional claims, where modifier CG serves the equivalent bypass function.
C1607 and C1608	Device pass-through categories approved with an effective date of January 1, 2026. CMS has indicated the associated applications will be discussed in the CY 2027 rulemaking.
C1741 and C1742	Device pass-through categories effective October 1, 2025. The C1741 long descriptor was revised to describe an absorbable metallic anchor or screw for bone fixation, directly relevant to musculoskeletal fixation cases.
Neurostimulator device codes	Generator, lead, and component codes differ by system type and by whether the device is rechargeable. Verify the applicable code for the specific system rather than carrying forward a prior assignment.
Interbody and instrumentation codes	Cage, plate, screw, rod, and connector coding varies. Confirm whether the components are separately reportable or packaged for the applicable payer.

Code or category	Application
L-codes	Orthotic and prosthetic codes. Generally a supplier benefit rather than an ASC facility service; do not assume ASC reportability.
Biologics and graft materials	Separately coded and separately covered. Verify coverage independently of the fusion or repair procedure.

Back to guide navigation

19

Diagnosis Documentation for Implant Procedures

Issue	Requirement
Specificity supporting the device indication	The diagnosis must support the indication for which the device is cleared or approved and which the payer policy covers. A diagnosis adequate for the procedure may be inadequate for the device.
Level and laterality	Must match the operative site and the device placement documented in the operative report.
Instability, deformity, and severity codes	Where the indication depends on instability, deformity, or a severity threshold, the diagnosis must reflect it rather than leaving it to narrative.
Prior device status	Codes describing the presence of a device, mechanical complication of a device, or device-related infection, where applicable to a revision.
Pseudarthrosis and nonunion	Where the indication is failed fusion, the diagnosis must state it. Omission of the complication or sequela code is a recurring gap in revision fusion documentation.
Consistency	The diagnosis must be consistent between the authorization request, the operative report, and the claim.

Back to guide navigation

20

Modifiers, Credits, and Place of Service

Modifier or code	Application in implant cases
FB	Device furnished without cost to the provider, or full credit received for a replaced device. Reported by ASCs; discontinued for hospital outpatient claims effective January 1, 2014.
FC	Partial credit of 50 percent or more of the device cost received. Reported by ASCs.
Value code FD with condition code 49, 50, or 53	The hospital outpatient mechanism for reporting device credits and no-cost initial placements. Not available on the ASC professional claim format.
CG	Hospital outpatient device edit bypass. Not the ASC mechanism; ASCs report C1890.
73 and 74	Discontinued procedure before or after anesthesia administration. Where an implant was opened before discontinuation, the cost is incurred without an implantable device to report.
50, RT, LT	Laterality and bilateral reporting, which must be consistent between the authorization, the operative report, the device documentation, and the claim.
POS 24	Ambulatory surgical center. Place of service drives the payment system and therefore the device payment mechanism.
GA and GX	Advance Beneficiary Notice pathways where a Medicare denial is anticipated, including where a device is expected to be non-covered.

Back to guide navigation

21

Implant Documentation and Authorization Checklist

Before the authorization request

• Anticipated implant system and components identified from the preference card and planned procedure
• Device coverage posture verified with the payer, separately from procedure coverage
• Contract reimbursement basis for the implant verified - packaged, carve-out, invoice plus, percentage of charges, or case rate
• Expected payment including device portion modeled against actual negotiated implant cost
• Delegation verified: whether device HCPCS codes are reviewed by the vendor for this member and product
• Device-level policy criteria identified and addressed in the submission
• Trial documentation assembled with measured response where a trial is required
• Off-label use, if applicable, addressed affirmatively

• Biologic or graft material coverage verified separately

Before the case

• Device-level determination captured in the facility record: category, system, quantity, limitations
• Authorized system confirmed available and on contract
• Consignment or loaner logistics arranged and sterilization documented
• Device reconciliation performed alongside the seven-field procedure reconciliation
• Substitution pathway understood by the operating room team

During and after the case

• Device detail captured at the point of use into the medical record: manufacturer, model, size, identifiers, site, level, laterality, quantity
• Any intra-operative substitution documented with clinical reason and flagged the same day
• Explanted device documented with identifiers and disposition
• Device HCPCS code assigned and verified against the ASC code pair file
• C1890 reported where a device-intensive procedure was performed without a device
• Device and procedure reported on the same claim and date of service
• Credit, no-cost, warranty, recall, trial, and sample devices routed from materials management to coding before claim submission
• FB or FC applied where supported, with documentation of the credit and amount
• Manufacturer invoice retained and submitted where the contract requires substantiation
• Device-level determination outcome recorded in structured fields for aggregate analysis

Back to guide navigation

22

Setting Comparison: Implant Payment in the ASC and the Hospital Outpatient Department

Dimension	Ambulatory surgery center	Hospital outpatient department
Claim format	Professional claim format	Institutional claim format

Dimension	Ambulatory surgery center	Hospital outpatient department
Default device payment	Packaged into the covered surgical procedure payment	Packaged into the APC payment, with comprehensive APC packaging where applicable
Device-intensive methodology	Applied, with the procedure paid at an adjusted rate reflecting the device portion	Applied, with device offset percentages published in the rule addenda
Pass-through	Applied; pass-through devices separately payable	Applied; the originating framework under section 1833(t)(6)(B)
No device used in a device-intensive procedure	Report C1890	Report modifier CG; C1890 is not reported on institutional claims
Device credit reporting	Modifiers FB and FC	Value code FD with condition code 49, 50, or 53; FB and FC discontinued January 1, 2014
Credit payment reduction	Device portion for no-cost or full credit; one-half the device offset for partial credit	Reduction consistent with 42 CFR 419.45, subject to the applicable limitation
Multiple procedure reduction	Applies, with the highest-valued procedure at full rate and additional procedures reduced	Comprehensive APC and other packaging structures apply
Practical implant cost exposure	Higher. Lower base payment against the same acquisition cost, with less ability to absorb a negative-margin case	Lower, with broader packaging but a larger payment base

Back to guide navigation

23

GoHealthcare Clinical Insights

Model the implant before you schedule the procedure

The most valuable control in implant operations is not an authorization control at all. It is a financial model built before a device-intensive procedure is added to the schedule, comparing expected payment including the device portion against actual negotiated implant cost for each system a surgeon may use. Facilities that do this decline some cases and renegotiate others. Facilities that do not discover the same information one remittance at a time.

Standardize implant systems where clinically acceptable

Preference card proliferation is the largest controllable driver of implant cost in most musculoskeletal ASCs. Standardization is a clinical governance conversation, not a purchasing mandate, and it succeeds only when surgeons participate in it. But the authorization benefit is real and under-recognized: a smaller device portfolio means fewer coverage postures to verify, fewer HCPCS assignments to maintain, fewer code pair relationships to track, and fewer device-level criteria to address.

Specify the device at authorization, always

Where device review rides with procedure delegation, omitting the device from the request does not avoid device review. It only ensures the review occurs without information. Specifying the anticipated device category costs nothing at submission and converts an unmanaged determination into a managed one.

Connect materials management to the business office

Device credit reporting, invoice substantiation, consignment reconciliation, and recall response all require information that lives in materials management and obligations that live in billing. In most facilities where we find failures in this domain, no one decided to fail; the two functions simply have no scheduled interface. A recurring meeting with a defined agenda resolves a surprising proportion of it.

Track pass-through expiration as a calendar event

Pass-through status runs at least two but not more than three years. A case economics model built on separate device payment becomes wrong on a knowable date. Pass-through categories in use should sit on the same operational calendar as the annual code update, with the expiration date and the modeled post-expiration margin recorded.

Audit the device edit before the payer does

Device edit denials are mechanical, fully preventable, and among the most common implant denials we see. A pre-submission check confirming that every J8 procedure carries either a device HCPCS code or C1890, and that the device code is permitted with the procedure, eliminates the category almost entirely.

Back to guide navigation

24

GoHealthcare Leadership Perspective

Implants convert authorization risk into balance sheet risk

In a non-implant ASC, an authorization failure costs a facility fee. In an implant-heavy ASC, it costs a facility fee plus an unrecoverable acquisition cost, and under several payer configurations it takes the professional and anesthesia claims with it. Organizations expanding into device-intensive musculoskeletal case mix are changing their risk profile in a way that should be visible to the governing body, and frequently is not.

The CY 2026 expansion is an opportunity with a precondition

The addition of 560 surgical procedures to the ASC Covered Procedures List and the phase-out of the Inpatient Only list represent genuine strategic opportunity. The precondition is infrastructure: implant supply chain and contracting, device authorization capability, device coding competence, cost modeling, and the clinical governance to make case selection decisions under a regime where CMS has explicitly transferred that judgment to physicians. A facility that adds the procedure without adding the infrastructure has purchased the risk without the return.

Contracting is where implant margin is actually determined

No amount of authorization discipline recovers a contract that packages a high-cost implant into a rate modeled on a low-cost case mix. Implant carve-out structure, invoice substantiation requirements, thresholds, percentages, and caps are the terms that determine whether device-intensive cases are viable. They should be negotiated with actual implant cost data in hand, and revisited whenever case mix shifts materially.

Device credit reporting is a compliance obligation, not a revenue option

Underreported device credits produce overpayments, and overpayments carry identification and return obligations. This has been a recurring focus of federal audit activity. Leadership should require a documented process linking materials management to billing, and should treat its absence as a compliance finding rather than an operational inconvenience.

What leadership should require

• A margin model for every device-intensive procedure on the schedule, by implant system, refreshed at the annual update and whenever a contract or preference card changes.
• Governing body visibility into case selection decisions for newly eligible high-acuity implant-bearing procedures.
• A documented interface between materials management, coding, and contracting, with defined cadence and agenda.
• Pass-through expiration tracked as a scheduled operational event with post-expiration margin modeled in advance.
• Device-level denial data captured in structured fields and reviewed in aggregate, separately from procedure denial data.
• A clinical governance process for implant standardization that surgeons participate in rather than receive.

• Verification that device-level authorization is being requested, not merely procedure authorization, wherever a vendor reviews device codes under delegation.

Back to guide navigation

25

GoHealthcare Case Study

The following is an original composite educational scenario. It does not describe any actual patient, clinician, facility, or organization.

Scenario

A musculoskeletal ASC expanded into single-level lumbar interbody fusion and permanent neurostimulator implantation following the CY 2026 Covered Procedures List expansion. Volume developed quickly. Within two quarters, implant-related write-offs exceeded the contribution margin of the entire new service line, and leadership initially attributed the problem to underpayment.

Findings on review

• For a subset of Medicare fusion cases, the facility had reported the procedure without a device HCPCS code. These denied on the device edit. Staff had been resubmitting them as clinical appeals, which failed, rather than correcting and resubmitting.
• For neurostimulator revision cases in which a generator was removed and repositioned without a new generator being furnished, the facility had reported a generator device code. This was incorrect; C1890 was the appropriate reporting. Several of these had paid, creating an overpayment exposure the facility had not identified.
• For a commercial payer delegating spine review to a utilization management vendor, the facility's authorization requests specified the procedure only. The vendor reviewed the associated device codes under the delegation and issued several partial determinations approving the fusion and denying the interbody device. Because the facility captured only an approval or denial flag rather than the determination detail, the partial determinations were recorded as approvals and the cases proceeded.
• Bone graft material used in fusion cases had never been separately verified for coverage. Two payers considered the specific material investigational.
• The facility's contract with its largest commercial payer packaged implants entirely into the procedure rate. That rate had been negotiated three years earlier against a case mix containing no interbody fusion.
• Warranty replacement generators supplied at no cost had been billed without modifier FB. Materials management tracked them; billing was never informed.

Analysis

Only one of the six findings was a payment rate problem. Two were mechanical coding failures, one was a compliance exposure running in the facility's favor and therefore invisible, one was an authorization capture failure, one was a coverage verification omission, and one was a contracting failure. The facility had diagnosed a rate problem because the aggregate symptom was insufficient payment. Without device-level denial data, no other diagnosis was available to it.

Resolution

• A pre-submission device edit check was implemented confirming that every device-intensive procedure carries either a device HCPCS code or C1890, verified against the current ASC code pair file.
• The neurostimulator revision coding was corrected prospectively, and the identified overpayments were evaluated and addressed through the facility's compliance process with counsel involvement.
• Authorization requests were revised to specify the anticipated device category and, where the policy addressed it, the specific system. Determination capture was expanded from a binary flag to structured fields recording device-level terms and limitations.

• A biologic and graft material coverage matrix was built and maintained separately from the procedure coverage matrix.
• Implant cost data was assembled by system and used to reopen the commercial contract, with an implant carve-out sought for interbody devices.

• A monthly materials management and business office interface was established with a standing agenda covering credits, no-cost devices, consignment reconciliation, and invoice substantiation.
• Device-level denial reasons were captured in structured fields and reported separately from procedure denials.

Outcome

Device edit denials were substantially eliminated within one cycle, being fully mechanical. Partial determinations became visible before the case rather than after, allowing several to be resolved pre-service and two cases to be appropriately redirected. The graft material matrix prevented recurrence of the coverage omission. The contract negotiation was still in progress at the time of review, but the facility was able to conduct it with implant cost data it had previously never assembled. Leadership's most significant change was the recognition that device-level and procedure-level denial data must be tracked separately, because aggregated they had concealed five distinct problems behind one symptom.

Lessons learned

• Aggregate denial data conceals device-specific failure modes. Device-level tracking is a prerequisite to managing implant economics.
• Mechanical edit denials must be classified as mechanical. Appealing them clinically wastes the timeline and never succeeds.
• A coding error that pays is more dangerous than one that denies, because nothing surfaces it.
• Capturing an authorization as approved or denied loses the information that matters most in device-intensive cases. Partial determinations are common and consequential.
• Graft and biologic coverage does not follow the fusion procedure and must be verified separately.
• Contract rates negotiated against a prior case mix do not survive a service line expansion. Expansion should trigger contract review as a matter of course.
• No-cost and credit device reporting fails silently wherever materials management and billing do not have a scheduled interface.

Back to guide navigation

26

GoHealthcare Best Practices

Domain	Practice
Financial modeling	Expected payment including device portion modeled against actual negotiated implant cost, by system, before any device-intensive procedure is added to the schedule.
Contracting	Implant carve-out structure, thresholds, percentages, caps, and substantiation requirements negotiated with implant cost data in hand and revisited on material case mix change.
Authorization	Device category or system specified in every request where the payer or vendor reviews device codes; device-level criteria addressed in the policy's own terms.
Determination capture	Structured capture of device-level authorization terms, including partial determinations and limitations, into the facility record.
Coverage verification	Biologic, graft, and adjunct material coverage verified separately from the procedure and maintained in its own matrix.
Device edit control	Pre-submission verification that every device-intensive procedure carries a device HCPCS code or C1890, validated against the current ASC code pair file.

Domain	Practice
Point-of-use capture	Device detail recorded into the medical record at the time of use, including intra-operative substitutions, never reconstructed from purchasing data.
Substitution management	Defined same-day pathway when the device used differs from the device authorized, with contemporaneous clinical documentation.
Credit and no-cost reporting	Documented routing from materials management to coding for warranty, recall, field action, clinical trial, and sample devices, before claim submission.
Pass-through tracking	Active pass-through categories and their expiration dates on the operational calendar, with post-expiration margin modeled in advance.
Update discipline	Device-intensive designations, payment indicators, code pair files, and pass-through categories reviewed at the annual update and at quarterly updates, not annually only.
Standardization	Implant standardization pursued as clinical governance with surgeon participation, reducing both cost and authorization complexity.
Measurement	Device-level denial reasons captured and reported separately from procedure-level denial reasons.

Back to guide navigation

27

Common Mistakes

• Assuming FDA clearance creates coverage. Three separate frameworks govern a device, and clearing one says nothing about the others.
• Assuming the procedure authorization covers the device. Where review is delegated, device HCPCS codes are commonly reviewed under the same delegation, and a partial determination is a real outcome.
• Omitting the device from the authorization request. This does not avoid device review; it ensures review without information.
• Capturing authorization as a binary approved or denied flag. Device-level terms and limitations are lost precisely where they matter most.
• Reporting a device HCPCS code for a device that was not furnished. In revision and removal cases without a new device, C1890 is the correct reporting. Reporting a device code that paid creates an overpayment.
• Omitting both a device code and C1890 on a device-intensive procedure. This triggers a mechanical device edit denial.
• Appealing a mechanical edit denial clinically. Correct and resubmit instead.
• Not verifying the code pair relationship. A device code outside its permitted pairing fails just as an absent code does.
• Splitting the device and procedure across claims or dates. Several commercial policies deny device-dependent procedures reported without the device on the same claim and date.
• Assuming graft and biologic coverage follows the fusion procedure. It does not, and several materials are treated as investigational.
• Recording implant detail only in a separate log. The medical record must contain it.
• Reconstructing implant documentation from purchasing records. Unreliable and indefensible.

• Failing to report device credits and no-cost devices. This is an overpayment with identification and return obligations, and an established audit target.
• Building case economics on pass-through payment without modeling its expiration. Pass-through runs at least two but not more than three years.

• Applying the hospital credit mechanism in the ASC. ASCs use FB and FC; value code FD and condition codes are not available on the professional claim format.
• Reviewing device codes and payment indicators annually only. Device operations require quarterly attention.
• Resting a device justification on surgeon preference. Reframe to the patient-specific attribute the system provides.

Back to guide navigation

28

Pearls and Pitfalls

Pearls

• Specify the device at authorization. It is free at submission and unrecoverable afterward.
• Treat C1890 as an affirmative reporting obligation rather than an obscure exception. Revision and removal cases are common in neuromodulation practice.
• Verify the code pair file, not just the code. Both the presence and the pairing must be right.

• Model implant margin per system, not per procedure. The same CPT® code carries very different economics across preference cards.
• Track device-level denials separately. Aggregation conceals exactly the failure modes that cost the most.
• Build the graft and biologic coverage matrix once. It prevents a recurring, expensive, and entirely avoidable oversight.
• For neurostimulation, treat the trial documentation as the permanent implant authorization, because functionally it is.

Pitfalls

• Device-intensive designation changes annually. A procedure designated one year may not be the next.
• Pass-through status expires on a knowable date, and the payment model changes with it.
• The default device offset for new codes is a rate-setting convention, not cost reimbursement, and applies precisely where cost exposure is highest.
• An implant opened but not implanted is a cost with no corresponding device to report.
• A coding error that results in payment does not surface itself and accrues overpayment exposure silently.
• Materials management systems are frequently retained for shorter periods than medical records, which matters for recall response and audit.
• Consignment and loaner inventory creates documentation obligations that owned inventory does not.
• Workers' compensation implant reimbursement is state-specific and may be materially better or worse than commercial; it must be modeled by state.
• Payment adequate for the procedure may be inadequate for the procedure plus the implant, and that is a contracting question rather than a claims question.

Back to guide navigation

29

Frequently Asked Questions

Q1. Does Medicare require separate prior authorization for an implant?

Generally no. Device payment is packaged into the procedure payment except where pass-through status applies, and there is no separate device authorization. The procedure itself may be subject to the hospital outpatient department program, the ASC demonstration, or the WISeR Model depending on setting and state, as addressed in Guide B04-01.

Q2. What makes a procedure device-intensive?

Effective January 1, 2019, a procedure involving the surgical implantation or insertion of an implantable device assigned a CPT® or HCPCS code, including single-use devices, where the device offset amount exceeds 30 percent of the procedure's mean cost.

Q3. What is the device offset?

The portion of the payment amount attributable to the device. It determines device-intensive qualification and the adjusted payment rate, and it is deducted from pass-through payment so the device is not paid twice. Device offset percentages and device portions are published in the annual ASC addenda.

Q4. What offset applies to a brand-new code with no claims data?

CMS applies a default device offset percentage that is the greater of 31 percent or the applicable APC device offset percentage. This is a rate-setting convention and should not be assumed to approximate a facility's actual acquisition cost.

Q5. What does payment indicator J8 mean?

Device-intensive procedure, paid at an adjusted rate. It signals that a device HCPCS code must accompany the procedure, or C1890 where no device was furnished.

Q6. What does payment indicator J7 mean?

OPPS pass-through device paid separately when provided integral to a covered surgical procedure. This is genuine separate payment, time-limited by the pass-through category.

Q7. How long does device pass-through status last?

Under section 1833(t)(6)(B) of the Social Security Act, device categories are eligible for transitional pass-through payment for at least two but not more than three years. CMS applies this policy in the ASC payment system as well.

Q8. Are there new pass-through categories relevant to musculoskeletal practice?

HCPCS C1607 and C1608 were approved for pass-through status effective January 1, 2026. C1741 and C1742 took effect October 1, 2025, and the C1741 long descriptor was revised to describe an absorbable metallic anchor or screw for bone fixation. Facilities should verify current status and permitted procedure pairings for any category they intend to bill.

Q9. What is C1890 and when is it used?

C1890 describes no implantable or insertable device used with device-intensive procedures. The ASC reports it alongside the device-intensive procedure code to signify that no device was furnished. It is payable in the ASC setting only and is not reported on hospital outpatient institutional claims, where modifier CG serves the equivalent function.

Q10. When would an ASC use C1890 in practice?

The most common scenario in musculoskeletal practice is a neurostimulator revision or removal in which an existing generator or component is repositioned or explanted without a new device being furnished. Reporting a device code for a device that was not supplied is incorrect.

Q11. What if the device has no specific HCPCS code?

Report C1889, implantable or insertable device not otherwise classified.

Q12. What is the ASC code pair file?

A CMS-published file identifying the CPT® codes an ASC must perform in conjunction with a given device HCPCS code. Reporting a device code outside its permitted pairing fails just as reporting no device code does.

Q13. Why did our device-dependent procedure deny?

Most commonly because no device HCPCS code and no C1890 was reported. The Medicare outpatient code editor identifies claims reporting a device-dependent procedure without at least one required device code, and denies mechanically. This is a correction-and-resubmission matter, not a clinical appeal.

Q14. Do commercial payers authorize the device separately?

Frequently yes, through the delegation structure. Where a CPT® code is delegated to a utilization management vendor, associated device HCPCS codes are commonly reviewed by that vendor for medical necessity under the same delegation. Some programs are explicitly designated as surgical and implantable device management programs.

Q15. Can a payer approve the procedure and deny the device?

Yes. A partial determination approving the procedure while denying or limiting the device is a real and consequential outcome, and it is the one that strands an implant cost. This is why authorization capture must record device-level terms rather than a binary flag.

Q16. Does authorization end the device review?

Not necessarily. At least one major implantable device management program reviews both professional and facility claims, with the plan reserving the right to adjust claims based on the vendor's recommendations.

Q17. How should we report a device furnished at no cost?

ASCs report modifier FB where a device was furnished without cost to the provider or full credit was received for a replaced device, and modifier FC where partial credit of 50 percent or more of the device cost was received. Documentation must support the credit and its amount.

Q18. Why do hospitals report device credits differently?

Hospitals report value code FD with condition code 49, 50, or 53; modifiers FB and FC were discontinued for hospital outpatient claims effective January 1, 2014. The ASC cannot use that mechanism because the professional claim format has no value code or condition code fields. Organizations operating both settings should maintain separate work instructions.

Q19. What is the payment effect of a device credit in the ASC?

For a no-cost or full-credit replacement device, ASC payment is reduced by the device portion of the ASC payment. For partial credit, the reduction is one-half of the device offset amount.

Q20. Is failing to report a device credit a significant exposure?

Yes. It produces an overpayment, and overpayments carry identification and return obligations. Device credit reporting has been a recurring focus of federal audit activity.

Q21. Is bone graft or biologic material covered because the fusion is covered?

No. Graft and biologic materials carry their own coverage positions, several of which are restrictive or treat specific materials as investigational. They must be verified separately. This is a frequent and expensive oversight.

Q22. What documentation does an implant require?

In the medical record: manufacturer, model, size, material where relevant, lot or serial number or unique device identifier, anatomic site, level, laterality, and quantity, captured at the point of use. A separate implant log is operationally useful but does not substitute for the medical record entry required by 42 CFR 416.47(b)(4).

Q23. What if the device used differs from the device authorized?

Code and document what was actually used, never what was authorized. Flag the variance the same day, with contemporaneous documentation of the clinical reason for the substitution, and pursue retrospective authorization or the payer's documented exception pathway.

Q24. How should a device denial be approached on appeal?

Classify it first. Mechanical edit denials are corrected and resubmitted. Device-not-authorized denials require establishing that the device was integral to the authorized procedure and addressing the device criteria never submitted. Investigational determinations are policy positions and rarely yield. Payment-below-cost is not appealable at all; it is a contracting matter.

Q25. How should off-label device use be handled at authorization?

Address it affirmatively with clinical justification, supporting literature, and an explanation of why labeled alternatives are not appropriate for this patient. Silence on off-label use is a common denial basis.

Q26. What documentation supports a neurostimulator permanent implant request?

The trial documentation, functionally. Trial dates, duration, measured response against the policy's stated threshold, functional change, and medication change. A trial documented as successful without measurement is the most common cause of denial for permanent implantation.

Q27. Should device selection rationale be documented?

Where the policy contains device-level criteria, yes. Frame it in patient-specific terms - anatomic fit, anticipated imaging need addressed by conditional labeling, revision compatibility with existing hardware, trial response to a specific waveform. Surgeon familiarity is a legitimate clinical consideration but is not a reviewable medical necessity argument.

Q28. What contract structures are used for implant reimbursement?

Fully packaged; implant carve-out at invoice, sometimes with a threshold; invoice plus a percentage, sometimes with a cap; percentage of billed charges; and case rate. Each carries a different risk profile, and each requires different substantiation discipline.

Q29. Does workers' compensation reimburse implants differently?

Frequently yes. Several state fee schedules address implant reimbursement explicitly, including invoice-plus-percentage formulas with per-item and per-admission caps and different treatment of device-intensive versus non-device-intensive procedures. It must be modeled by state.

Q30. How often should device coding references be reviewed?

At the annual update and at quarterly updates. Device-intensive designations, payment indicators, code pair files, and pass-through categories all change on published cycles, and device operations are more sensitive to quarterly change than most other ASC functions.

Q31. What is the single highest-yield control in implant operations?

Two, and they operate at different points. Financially: modeling expected payment including the device portion against actual negotiated implant cost, by system, before a device-intensive procedure is scheduled. Operationally: a pre-submission device edit check confirming every device-intensive procedure carries a device HCPCS code or C1890, verified against the current code pair file.

Back to guide navigation

30

Key Takeaways

• Three frameworks govern an implant - FDA regulatory status, coverage, and payment. Clearing one says nothing about the others.
• Medicare generally does not authorize implants separately; device payment is packaged except under pass-through. The operative issues are coding, documentation, and correct application of the device-intensive methodology.
• A device-intensive procedure is one involving an implantable device with a device offset exceeding 30 percent of the procedure's mean cost. New codes without claims data receive a default offset that is the greater of 31 percent or the applicable APC offset.
• Payment indicator J8 identifies device-intensive procedures; J7 identifies pass-through devices paid separately. Pass-through runs at least two but not more than three years and expires on a knowable date.
• Every device-intensive procedure must carry a device HCPCS code or, where no device was furnished, C1890. Omitting both produces a mechanical edit denial. C1890 is an ASC-only code; hospitals use modifier CG.
• The device code must also be permitted with the procedure under the ASC code pair file.
• Under the common commercial delegation structure, device HCPCS codes are reviewed by the same vendor that reviews the delegated procedure code. Omitting the device from the request does not avoid review; it ensures review without information.
• Partial determinations approving the procedure and denying the device are real, consequential, and invisible to facilities that capture authorization as a binary flag.
• ASCs report device credits with modifiers FB and FC; hospitals use value code FD with condition codes. Unreported credits are overpayments and an established audit target.
• Graft and biologic material coverage does not follow the fusion procedure and must be verified separately.
• Implant detail must be in the medical record, captured at the point of use. A separate log is not a substitute.

• The binding constraint in device-intensive ASC cases is frequently contracting rather than authorization. Payment below implant cost is not a claims problem and cannot be appealed.

Back to guide navigation

31

Future Outlook

Implant-bearing procedures continue migrating into the ASC

The CY 2026 Covered Procedures List expansion and the three-year Inpatient Only list phase-out are predominantly musculoskeletal, and musculoskeletal is predominantly implant-bearing. Facilities should expect the proportion of case

value represented by implants to rise, and with it the consequence of every failure mode in this guide.

Device-level utilization management expands

Programs explicitly designated as surgical and implantable device management, in which device codes are reviewed under the same delegation as the procedure and claims are reviewed post-service, represent a maturation of utilization management from procedure appropriateness toward device appropriateness and cost. The reasonable planning assumption is more device-level criteria, applied to more device categories, by more payers.

Unique device identification and traceability

Unique device identifier capture is becoming more consistently expected, and the infrastructure supporting it is maturing. Facilities that capture identifiers reliably at the point of use will be positioned for recall response, registry participation, and any future payer substantiation requirement; those relying on purchasing records will not.

Structured data and electronic authorization

The CMS-0057-F interface requirements applicable to affected payers generally by January 1, 2027 will make structured data the currency of authorization. Device specification is well suited to structured capture, and facilities that record anticipated device category as discrete data will be better positioned than those handling it in narrative.

Cost pressure meets rising device cost

The structural tension in ASC implant economics - a payment system built on packaging meeting a device market with rising acquisition costs and rapid innovation - is not resolving. Pass-through provides temporary relief for genuinely new categories and then expires. Facilities should expect to make explicit case selection decisions on economic grounds more often, and should make them through clinical governance rather than at the scheduling desk.

Robotics, navigation, and enabling technology

Enabling technologies used alongside implants carry their own coverage postures, frequently more restrictive than the implant itself, and their capital cost sits outside the device offset entirely. As these technologies move into the ASC with the procedures they support, they will require their own coverage verification and their own financial modeling.

Back to guide navigation

32

References

1. Centers for Medicare & Medicaid Services. Calendar Year 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center Final Rule (CMS-1834-FC), Fact Sheet. Website: https://www.cms.gov/newsroom/fact-sheets/calendar-ye ar-2026-hospital-outpatient-prospective-payment-system-opps-ambulatory-surgical-center

2. Centers for Medicare & Medicaid Services. Ambulatory Surgical Center Payment System program page, including annual and quarterly addenda, payment indicators, code pair files, and Addendum FF device offset percentages and device portions. Website: https://www.cms.gov/medicare/payment/prospective-payment-systems/ambulatory-surgical-center-asc

3. Centers for Medicare & Medicaid Services. MLN Matters MM14359: Ambulatory Surgical Center Payment System January 2026 Update. Website: https://www.cms.gov/files/document/mm14359-ambulatory-surgical-center-payment-january-2026-update.pdf

4. Centers for Medicare & Medicaid Services. MLN Matters MM14361: Hospital Outpatient Prospective Payment System January 2026 Update. Website: https://www.cms.gov/files/document/mm14361-hospital-outpatient-prospective-payment-system-january-2026-update.pdf

5. Centers for Medicare & Medicaid Services. MLN Matters MM14246: Ambulatory Surgical Center Payment System October 2025 Update. Website: https://www.cms.gov/files/document/mm14246-ambulatory-surgical-center-payment-system-october-2025-update.pdf

6. Centers for Medicare & Medicaid Services. MLN Matters MM14445: Ambulatory Surgical Center Payment System April 2026 Update. Website: https://www.cms.gov/files/document/mm14445-ambulatory-surgical-center-payment-system-april-2026-update.pdf

7. Centers for Medicare & Medicaid Services. Transmittal R4204CP, establishing HCPCS C1890 and the device-intensive procedure policy changes effective January 1, 2019. Website:

https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2019Downloads/R4204CP.pdf

8. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual, Publication 100-04, Chapter 4 (Part B Hospital), including sections addressing billing for devices furnished without cost or with credit, and Chapter 14 (Ambulatory Surgical Centers). Website: https://www.cms.gov/medicare/regulations-guidance/manuals/internet-only-manuals-ioms

9. Electronic Code of Federal Regulations. 42 CFR 419.45 - Payment and copayment reduction for devices replaced without cost or when full or partial credit is received. Website: https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-419/subpart-D/section-419.45

10. Electronic Code of Federal Regulations. 42 CFR Part 416 - Ambulatory Surgical Services. Website: https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-416

11. Social Security Act, section 1833(t)(6) - Transitional pass-through payments. Website: https://www.ssa.gov/OP_Home/ssact/title18/1833.htm

12. Centers for Medicare & Medicaid Services. Medicare Coverage of Investigational Device Exemption (IDE) Studies. Website: https://www.cms.gov/medicare/coverage/investigational-device-exemption-ide-studies

13. Electronic Code of Federal Regulations. 42 CFR Part 405, Subpart B - Medical services coverage decisions that relate to health care technology, including investigational device categorization. Website: https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-405/subpart-B

14. U.S. Food and Drug Administration. Premarket Notification 510(k). Website: https://www.fda.gov/medical-devices/premarket-submis sions-selecting-and-preparing-correct-submission/premarket-notification-510k

15. U.S. Food and Drug Administration. Premarket Approval (PMA). Website: https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-approval-pma

16. U.S. Food and Drug Administration. Humanitarian Device Exemption. Website: https://www.fda.gov/medical-devices/premarket-sub missions-selecting-and-preparing-correct-submission/humanitarian-device-exemption

17. U.S. Food and Drug Administration. Investigational Device Exemption (IDE). Website: https://www.fda.gov/medical-devices/premark et-submissions-selecting-and-preparing-correct-submission/investigational-device-exemption-ide

18. U.S. Food and Drug Administration. Unique Device Identification System (UDI System). Website: https://www.fda.gov/medical-devic es/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system

19. U.S. Food and Drug Administration. MAUDE - Manufacturer and User Facility Device Experience database. Website: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm

20. U.S. Department of Health and Human Services, Office of Inspector General. Reports and audits addressing medical device credit reporting. Website: https://oig.hhs.gov

21. TurningPoint Healthcare Solutions. Provider resources and program information. Website: https://www.turningpoint-healthcare.com

22. Evolent. Provider resources. Website: https://www.evolent.com

23. eviCore healthcare. Clinical guidelines. Website: https://www.evicore.com/provider/clinical-guidelines

24. Carelon Medical Benefits Management. Clinical appropriateness guidelines. Website: https://guidelines.carelonmedicalbenefitsmanagement.com

25. Cohere Health. Provider resources. Website: https://coherehealth.com

26. UnitedHealthcare. Device, Implant, and Skin Substitute Policy, Facility. Website: https://www.uhcprovider.com

27. Aetna. Clinical Policy Bulletins. Website: https://www.aetna.com/health-care-professionals/clinical-policy-bulletins.html

28. Cigna Healthcare. Coverage policies. Website: https://static.cigna.com/assets/chcp/resourceLibrary/coveragePolicies/

29. Humana. Medical and pharmacy coverage policies. Website: https://www.humana.com/provider/medical-resources/clinical/coverage-policies

30. Ambulatory Surgery Center Association. Implant and device resources. Website: https://www.ascassociation.org

31. North American Spine Society. Coverage recommendations and clinical guidelines. Website: https://www.spine.org

32. American Academy of Orthopaedic Surgeons. Clinical practice guidelines. Website: https://www.aaos.org

33. International Neuromodulation Society. Website: https://www.neuromodulation.com

34. North American Neuromodulation Society. Website: https://www.neuromodulation.org

35. American Society of Interventional Pain Physicians. Website: https://www.asipp.org

36. American Medical Association. CPT® Current Procedural Terminology. Website: https://www.ama-assn.org/practice-management/cpt

Back to guide navigation

33

Reading Recommendations

• The current-year ASC addenda in full, specifically Addendum AA for covered surgical procedures and payment indicators, Addendum DD1 for payment indicator definitions, Addendum EE for excluded procedures, and Addendum FF for device offset percentages and device portions.

• The current ASC code pair file, which is the authoritative source for permitted device and procedure pairings and is not reproducible from any secondary summary.
• The quarterly MLN Matters articles updating the ASC and hospital outpatient payment systems, which carry new pass-through categories, descriptor revisions, and offset updates between annual rules.
• The device-intensive procedure list in the current rule addenda, reviewed against the facility's actual case mix.

• Medicare Claims Processing Manual Chapter 4 sections addressing devices furnished without cost or with credit, read alongside 42 CFR 419.45.
• The clinical criteria of whichever utilization management vendor governs the facility's largest commercial volume, with specific attention to any device consideration section.
• Current manufacturer labeling for each implant system in regular use, for cleared or approved indications and MRI conditionality.
• FDA Unique Device Identification System guidance, for facilities building point-of-use identifier capture.
• Peer-reviewed outcome literature for implant-bearing procedures newly moving into the ambulatory setting, in sources such as The Spine Journal, Spine, the Journal of Bone and Joint Surgery, and Neuromodulation.

Back to guide navigation

34

Related GoHealthcare Resources

Guide	Focus	Status
B04-01 - ASC Prior Authorization	The three concurrent Medicare prior authorization regimes, commercial site-of-service review, and facility versus professional authorization.	Published
B04-02 - ASC Documentation Requirements	Conditions for Coverage, medical record standards, the 2019 history and physical policy change, and survey readiness.	Published
B04-03 - Implant Authorization	This guide.	Published
B04-04 - Medical Device Coverage	FDA regulatory pathways in depth, device-specific coverage positions by payer, investigational device determinations, and emerging technology coverage.	Planned
B04-05 - Same-Day Surgery Documentation	The intra-operative and perioperative record, including implant capture at the point of use.	Planned
B04-06 - Observation versus Outpatient	The 24-hour standard, extended recovery, and case selection for higher-acuity implant cases.	Planned
B04-07 - Medicare ASC Billing	ASC payment system mechanics in depth, including device-intensive payment calculation and packaging.	Planned
B04-08 - Commercial ASC Billing	Contract structures, implant carve-outs, invoice substantiation, and balance billing protections.	Planned
B04-09 - Revenue Cycle for ASCs	End-to-end revenue cycle design, implant margin analytics, and denial management.	Planned
B04-10 - Compliance and Accreditation	Compliance program design, including device credit reporting and overpayment obligations.	Planned

Procedure-specific device content appears in the individual procedure guides of the GoHealthcare MSK Specialty Procedure Library™, including the neuromodulation, lumbar spine surgical, and facet joint intervention series. Website: https://www.gohealthcarellc.com

Back to guide navigation

35

Recommended Downloads

• Implant Margin Model template - expected payment including device portion against actual negotiated implant cost, by procedure and by system.
• Device Edit Pre-Submission Checklist - verification that every device-intensive procedure carries a device HCPCS code or C1890, validated against the current code pair file.

• Device Authorization Specification worksheet - structured capture of anticipated device category, system, components, and quantity for inclusion in the authorization request.
• Device-Level Determination Capture form - structured recording of device-level authorization terms, limitations, and partial determinations.
• Biologic and Graft Material Coverage Matrix - coverage posture by payer for graft materials, bone substitutes, and biologics, maintained separately from procedure coverage.
• Point-of-Use Implant Capture form - manufacturer, model, size, identifiers, site, level, laterality, and quantity, designed for the operative record.
• Device Credit Routing Protocol - defined process linking materials management to coding for warranty, recall, field action, clinical trial, and sample devices.
• Pass-Through Category Tracker - active categories, effective dates, expiration dates, and modeled post-expiration margin.
• Implant Contract Term Comparison - carve-out structure, thresholds, percentages, caps, and substantiation requirements by payer.
• Intra-Operative Substitution Escalation form - same-day documentation and routing when the device used differs from the device authorized.

Back to guide navigation

36

Visual Recommendations

Visual	Purpose	Placement
Three-framework diagram	FDA regulatory status, coverage, and payment as three independent gates a device must pass.	Regulatory and Payment Foundation section.
Device payment decision tree	Branching logic from payment indicator through device code selection, C1889, C1890, and code pair verification.	Medicare Payment Architecture section.
Device offset illustration	Visual breakdown of a device-intensive procedure payment into device portion and service portion, with the pass-through offset deduction shown.	Regulatory and Payment Foundation section.
Delegation rider diagram	How device HCPCS review attaches to procedure code delegation, and where partial determinations arise.	When Implant Authorization Is Triggered section.
ASC versus HOPD credit reporting comparison	Side-by-side of FB and FC against value code FD with condition codes, with the claim format rationale.	Medicare Payment Architecture section.
Implant workflow swimlane	Preference card through claim, across surgeon, materials management, authorization, scheduling, operating room, coding, and billing.	Implant Authorization Workflow section.
Pass-through lifecycle timeline	Category approval through the two-to-three year window to expiration, with the margin inflection marked.	Medicare Payment Architecture section.

Visual	Purpose	Placement
Implant margin waterfall	Expected payment through device portion, acquisition cost, and net contribution, illustrating where negative-margin cases arise.	Leadership Perspective section.
Device documentation card	Point-of-use capture elements formatted for operating room use.	Implant Documentation section.
Denial classification matrix	Device denial types mapped to mechanical, clinical, policy, and contractual categories with the corresponding response.	Appeal Considerations section.

Back to guide navigation

38

Educational Disclaimer

Educational Disclaimer, Limitations, and Terms of Use

This guide is provided for educational and operational reference purposes only. By reading, distributing, or relying on this document, you acknowledge and accept the terms set out in this section in their entirety. If you do not accept these terms, do not use this document.

1. Purpose and scope

This guide addresses the operational, documentation, coverage, medical necessity, prior authorization, utilization management, coding, and compliance considerations that surround the delivery of musculoskeletal specialty care. It is a practice operations resource. It is expressly not a clinical textbook, a procedural technique manual, a physician training guide, a specialty society practice guideline, a coding manual, a payer policy manual, or a legal treatise.

This guide does not provide, and must not be used as a source of, procedural or surgical technique, needle or instrument placement instruction, anesthesia technique, medication selection or dosing, imaging technique, device programming, or any other instruction bearing on the physical performance of a procedure on a patient.

2. No professional advice and no professional relationship

Nothing in this guide constitutes medical, nursing, legal, regulatory, compliance, accounting, tax, actuarial, coding, billing, reimbursement, or consulting advice. Reading or relying on this guide does not create a physician-patient relationship, a clinician-patient relationship, an attorney-client relationship, an accountant-client relationship, a consulting engagement, or any other professional, contractual, or fiduciary relationship with GoHealthcare Practice Solutions, with its officers, employees, or contractors, or with the author.

Readers should obtain advice from their own qualified clinical, legal, compliance, coding, and reimbursement professionals with respect to their specific facts, jurisdiction, payer contracts, and circumstances before acting on any information in this guide.

3. Independent clinical judgment governs all patient care

All decisions regarding patient evaluation, diagnosis, treatment selection, procedure selection, patient selection, anesthesia planning, site of service, and discharge are the exclusive responsibility of the treating licensed clinician exercising independent professional judgment for the individual patient. This guide does not, and cannot, account for any individual patient's clinical presentation, comorbidities, preferences, or circumstances. No content in this guide should be permitted to influence a clinical decision away from what the treating clinician judges to be in the patient's best interest.

4. Coverage, coding, and payment information is time-limited and may be superseded

National Coverage Determinations, Local Coverage Determinations, Local Coverage Articles, CMS manuals, transmittals, program instructions, demonstration and model parameters, commercial medical policies, utilization management vendor criteria, code sets, code descriptors, payment indicators, covered procedure lists, conversion factors, and quality reporting requirements all change frequently, are revised on differing cycles, may be applied differently by different contractors and jurisdictions, and may be amended, corrected, suspended, delayed, or withdrawn without notice.

All statements in this guide reflect publicly available authoritative sources as understood on the publication date stated in the Document History section. They may have been superseded by the time you read this. The reader is solely responsible for verifying every requirement against the primary source and the payer policy actually in effect on the applicable date of service. Where this guide and a primary source conflict, the primary source governs.

5. No guarantee of authorization, coverage, payment, or outcome

GoHealthcare Practice Solutions makes no representation, warranty, prediction, or guarantee that following any recommendation, checklist, template, workflow, or strategy described in this guide will result in prior authorization approval, affirmation, coverage, payment, reimbursement at any particular level, a successful appeal, avoidance of a peer-to-peer review, avoidance of audit or medical review, or any other outcome. Authorization is not a guarantee of payment. Payment is subject to eligibility, benefit design and limits, network status, coding accuracy, timely filing, medical necessity, contract terms, and all other applicable requirements.

6. Site-of-service and utilization content

This guide describes differences among care settings, including differences in coverage rules, prior authorization requirements, payment systems, and administrative burden. This descriptive content is provided so that operational teams can execute correctly in whichever setting the treating clinician selects.

It is not, and must not be construed as, guidance to select or steer a site of service, a procedure, a code, or a patient population for economic reasons, for the purpose of avoiding prior authorization or utilization review, or for any purpose other than the clinical appropriateness and safety of the individual patient. Site-of-service selection must be driven by clinical appropriateness, patient safety, and applicable regulatory and accreditation requirements. Patterns of setting, procedure, or coding selection that are not clinically grounded may implicate the Federal Anti-Kickback Statute, the physician self-referral law, the False Claims Act, the Civil Monetary Penalties Law, beneficiary inducement prohibitions, state corporate practice and fee-splitting laws, state insurance law, and payer contract terms. Readers should obtain legal counsel before adopting any practice that could be characterized as steering.

7. Compliance and program integrity remain the reader's responsibility

Nothing in this guide should be interpreted as encouraging, endorsing, or excusing the submission of any claim, code, modifier, diagnosis, or authorization request that is not fully supported by the contemporaneous medical record and by the service actually furnished. Documentation must reflect the care that was delivered. Coding must reflect the documentation. Any authorization request or claim submitted under a provider's identifier is that provider's representation, regardless of who prepared it and regardless of whether any template, tool, or automation was used in its preparation.

Each organization is solely responsible for its own compliance program, coding and billing accuracy, medical record integrity, licensure and accreditation obligations, privacy and security obligations, and adherence to all applicable federal, state, and local law and to all applicable payer contract terms.

8. Intellectual property and third-party content

• CPT® is a registered trademark of the American Medical Association. CPT® is copyright of the American Medical Association. All rights reserved. Any CPT® code references in this guide are provided for educational identification only and any descriptor language is paraphrased. This guide does not convey any license to use CPT® content. Users must obtain a license directly from the American Medical Association. Website: https://www.ama-assn.org
• HCPCS Level II codes and ICD-10-CM codes are maintained by the Centers for Medicare & Medicaid Services, the National Center for Health Statistics, and other responsible authorities. Code references are educational and are not a substitute for the official code sets and official coding guidelines.
• Commercial payer medical policies and utilization management vendor clinical criteria - including but not limited to those of eviCore, Carelon Medical Benefits Management, Cohere Health, Evolent, TurningPoint Healthcare Solutions, UnitedHealthcare, Aetna, Cigna Healthcare, Humana, Elevance Health, and Blue Cross Blue Shield licensees - are the proprietary property of their respective owners and may be subject to their own terms of use. This guide synthesizes and summarizes requirements at a general operational level and does not reproduce, republish, or substitute for those materials. Readers must consult the current policy or criteria document directly, under whatever license or terms of access apply to them.
• All other trademarks, service marks, product names, device names, and organization names referenced in this guide are the property of their respective owners and are used for identification purposes only.

9. No endorsement

References to any payer, health plan, utilization management vendor, device or implant manufacturer, accrediting organization, professional society, publication, product, service, or organization are for identification and educational purposes only. They do not constitute an endorsement, recommendation, certification, or warranty by GoHealthcare Practice Solutions, and they do not imply any affiliation, sponsorship, partnership, or relationship with, or approval by, any such entity.

10. Third-party websites and links

This guide includes website addresses for authoritative primary sources as a convenience. GoHealthcare Practice Solutions does not control those sites and is not responsible for their content, availability, accuracy, currency, or terms of use. Inclusion of an address does not constitute endorsement of the site or its operator. Addresses may change or cease to function after publication.

11. Case studies, examples, templates, and checklists

All case studies, scenarios, examples, and quantitative illustrations in this guide are original composite educational constructions. They do not describe, and are not derived from, any actual patient, clinician, facility, health plan, or organization. Any resemblance to an actual person or entity is unintended and coincidental. No protected health information is contained in this guide.

Any checklist, template, workflow, matrix, or framework offered in this guide is a starting point requiring adaptation to the reader's own setting, payer mix, contracts, state law, accreditation standards, and clinical program. It should be reviewed and approved by the reader's own clinical, compliance, and legal leadership before adoption.

12. Preparation, verification status, and known limitations

This guide was prepared using publicly available authoritative sources. It was prepared without live access to proprietary payer policy databases, licensed code set databases, claims adjudication systems, or subscription clinical criteria platforms. Notwithstanding the verification performed, the reader should assume the possibility of error, omission, ambiguity, or subsequent supersession, and should independently verify any point on which the reader intends to rely. The verification and review status of this specific guide is recorded in the Document History section and should be consulted before operational use.

13. No warranty

This guide is provided "as is" and "as available," without warranty of any kind, whether express, implied, or statutory, including without limitation any implied warranty of accuracy, completeness, currency, reliability, title, non-infringement, merchantability, or fitness for a particular purpose. GoHealthcare Practice Solutions does not warrant that the information in this guide is accurate, complete, current, or applicable to any particular circumstance.

14. Limitation of liability

To the fullest extent permitted by applicable law, neither GoHealthcare Practice Solutions nor its officers, directors, members, employees, contractors, agents, or the author shall be liable for any direct, indirect, incidental, consequential, special, exemplary, or punitive damages, or for any loss of revenue, profit, reimbursement, data, goodwill, or business opportunity, or for any claim denial, recoupment, penalty, sanction, audit finding, or regulatory action, arising out of or in connection with the use of, reliance on, or inability to use this guide, whether based in contract, tort, negligence, strict liability, or any other theory, and whether or not advised of the possibility of such damages.

15. Copyright and permitted use

© 2026 GoHealthcare Practice Solutions. All rights reserved. GoHealthcare MSK Specialty Procedure Library™ and the GoHealthcare Clinical Procedure Guide Standard™ are marks of GoHealthcare Practice Solutions. This guide may be read, printed, and shared internally within a healthcare organization for its own educational and operational purposes, provided it is reproduced in full, without alteration, and with all attribution and this disclaimer intact. It may not be resold, relabeled, incorporated into a commercial product or training program, or republished externally without prior written permission.

16. Corrections and feedback

GoHealthcare Practice Solutions welcomes correction. If you identify an error, an omission, or a superseded requirement in this guide, please contact us so that it can be evaluated and addressed in a subsequent version. Website: https://www.gohealthcarellc.com

In Short

Summary. Verify everything against the primary source and the payer policy in effect on the date of service. Let clinical judgment govern patient care and site of service. Document what was actually done. Obtain your own legal and compliance advice. This guide informs your process; it does not assume your risk.

GoHealthcare Practice Solutions is a national Musculoskeletal Specialty Management Services Organization supporting Pain Management, Orthopedic Surgery, Spine Surgery, Neurosurgery, Neuromodulation, and Ambulatory Surgery Centers. Website: https://www.gohealthcarellc.com

Back to guide navigation

Developed by

Pinky Maniri

MSc, BSc, CRCR, CSAPM, CSPPM, CSBI, CSPR, CSAF, Certified in Healthcare A.I. Governance

Founder and Chief Executive Officer, GoHealthcare Practice Solutions

LinkedInGoHealthcare

Strengthen ASC documentation, authorization, and revenue integrity.

GoHealthcare Practice Solutions helps musculoskeletal specialty organizations translate payer, regulatory, documentation, coding, and operational requirements into reliable workflows.

Request HelpExplore the Procedure Library